All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
Bookmark this article
During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Rachel Rau, Texas Children's Hospital, Houston, US. We asked, How does MRD guide therapeutic decisions in ALL?
How does MRD guide therapeutic decisions in ALL?
Rau begins by outlining the two main modalities with which MRD is measured, multiple parameter flow cytometry or PCR. Rau goes on to explain when to test MRD and the correlation between a poor prognosis and a higher MRD. She discusses high risk patients in ALL and the possible treatment options for patients who are still MRD positive after consolidation. Finally, Rau highlights that the future may hold further investigation into more sensitive assays, to further risk stratify patients, such as the clonoSEQ assay.
Your opinion matters
Which factors influence the need for allo-SCT consolidation in patients treated with CAR T-cells?
During the 6th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM 2021), the ALL Hub was pleased to...
Humoral and cellular responses to tisagenlecleucel
Chimeric antigen receptor (CAR) T-cell therapy has elicited high-response rates in patients with relapsed or refractory (R/R) B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL) and...
Subscribe to get the best content related to ALL delivered to your inbox